These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 16575773)

  • 21. The medical, social, and functional profile of Parkinson's disease patients.
    Lee KS; Merriman A; Owen A; Chew B; Tan TC
    Singapore Med J; 1994 Jun; 35(3):265-8. PubMed ID: 7997900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Motor complications in Parkinson's disease: ten year follow-up study.
    López IC; Ruiz PJ; Del Pozo SV; Bernardos VS
    Mov Disord; 2010 Dec; 25(16):2735-9. PubMed ID: 20931632
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The health burdens of Parkinson's disease.
    Chrischilles EA; Rubenstein LM; Voelker MD; Wallace RB; Rodnitzky RL
    Mov Disord; 1998 May; 13(3):406-13. PubMed ID: 9613729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Dyskinesia in Parkinson's disease--major clinical features, aetiology, therapy].
    Ellrichmann G; Russ H; Müller T
    Fortschr Neurol Psychiatr; 2007 Jul; 75(7):387-96. PubMed ID: 17443441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the direct and indirect costs associated with Parkinson's disease.
    Rodríguez-Blázquez C; Forjaz MJ; Lizán L; Paz S; Martínez-Martín P
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):889-911. PubMed ID: 26511768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The scientific basis for the current treatment of Parkinson's disease.
    Olanow CW
    Annu Rev Med; 2004; 55():41-60. PubMed ID: 14746509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.
    Merola A; Zibetti M; Angrisano S; Rizzi L; Ricchi V; Artusi CA; Lanotte M; Rizzone MG; Lopiano L
    Brain; 2011 Jul; 134(Pt 7):2074-84. PubMed ID: 21666262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease.
    De Reuck J; De Weweire M; Van Maele G; Santens P
    J Neurol Sci; 2005 Apr; 231(1-2):35-9. PubMed ID: 15792818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term stability of effects of subthalamic stimulation in Parkinson's disease: Indian Experience.
    Kishore A; Rao R; Krishnan S; Panikar D; Sarma G; Sivasanakaran MP; Sarma S
    Mov Disord; 2010 Oct; 25(14):2438-44. PubMed ID: 20976738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors of subthalamic stimulation in Parkinson's disease: a comparative study between short- and long-term effects.
    Tsai ST; Lin SH; Chou YC; Pan YH; Hung HY; Li CW; Lin SZ; Chen SY
    Stereotact Funct Neurosurg; 2009; 87(4):241-8. PubMed ID: 19556833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease severity and health-related quality of life across different chronic conditions.
    Ferrucci L; Baldasseroni S; Bandinelli S; de Alfieri W; Cartei A; Calvani D; Baldini A; Masotti G; Marchionni N
    J Am Geriatr Soc; 2000 Nov; 48(11):1490-5. PubMed ID: 11083330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Parkinson's disease: a long and difficult journey.
    Casey G
    Nurs N Z; 2013 Aug; 19(7):20-4. PubMed ID: 24195263
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease.
    Post B; Muslimovic D; van Geloven N; Speelman JD; Schmand B; de Haan RJ;
    Mov Disord; 2011 Feb; 26(3):449-56. PubMed ID: 21312273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.
    Chen JJ
    Am J Manag Care; 2010 Mar; 16 Suppl Implications():S87-93. PubMed ID: 20297871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease].
    Cubo E; Martínez Martin P; González M; Frades B;
    Neurologia; 2009; 24(1):15-23. PubMed ID: 19003550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life in Parkinson's disease--Indian scenario.
    Ray J; Das SK; Gangopadhya PK; Roy T
    J Assoc Physicians India; 2006 Jan; 54():17-21. PubMed ID: 16649733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationships between disability, quality of life and prevalence of nonmotor symptoms in Parkinson's disease.
    Leonardi M; Raggi A; Pagani M; Carella F; Soliveri P; Albanese A; Romito L
    Parkinsonism Relat Disord; 2012 Jan; 18(1):35-9. PubMed ID: 21880537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease.
    Weintraub D; Moberg PJ; Duda JE; Katz IR; Stern MB
    J Am Geriatr Soc; 2004 May; 52(5):784-8. PubMed ID: 15086662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of motor symptoms upon the quality of life of patients with Parkinson's disease.
    Gómez-Esteban JC; Zarranz JJ; Lezcano E; Tijero B; Luna A; Velasco F; Rouco I; Garamendi I
    Eur Neurol; 2007; 57(3):161-5. PubMed ID: 17213723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.